13F-HR filed by Fairmount Funds Management LLC
Fairmount Funds Management LLC filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 16 holding rows worth $946,456,168.
- Accession
- 0001104659-24-023531
- Filer
- CIK 1802528
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 16 entries on the cover page, a total value of $946,456,168 stated on the cover page (in dollars after the unit check, H1), rows summing to $946,456,168 with VALUE read as dollars as filed, 13F file number 028-19908. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| AXSOME THERAPEUTICS INC. COM | 05464T104 | Stock | 2,360,077 | $187,838,528 | dollars as filed | |
| IMMUNOGEN INC | 45253H101 | COMMON STOCK | 5,929,592 | $175,812,403 | dollars as filed | |
| NUVALENT INC COM | 670703107 | Stock | 1,924,626 | $141,633,227 | dollars as filed | |
| APOGEE THERAPEUTICS INC COM | 03770N101 | Stock | 2,941,176 | $82,176,457 | dollars as filed | |
| RAYZEBIO INC | 75525N107 | COM | 1,245,929 | $77,459,406 | dollars as filed | |
| KINIKSA PHARMACEUTICALS LTD | G5269C101 | COM CL A | 2,883,221 | $50,571,696 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 112,903 | $42,951,688 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 1,369,623 | $29,830,389 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 2,131,369 | $29,498,147 | dollars as filed | |
| ASTRIA THERAPEUTICS INC COM | 04635X102 | Stock | 3,554,129 | $27,295,711 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 3,558,975 | $20,926,773 | dollars as filed | |
| DIANTHUS THERAPEUTICS INC | 252828108 | COM | 1,928,503 | $20,056,431 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 717,254 | $19,724,485 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 1,393,329 | $19,297,607 | dollars as filed | |
| TERNS PHARMACEUTICALS INC COM | 880881107 | Stock | 2,040,000 | $13,239,600 | dollars as filed | |
| SPYRE THERAPEUTICS INC | 00773J202 | COM NEW | 378,421 | $8,143,620 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-24-023531 | this filing | 2024-02-14 | acceptance time not in the bulk data set |